Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Short-term Investments (2021 - 2025)

Caribou Biosciences has reported Short-term Investments over the past 5 years, most recently at $127.0 million for Q4 2025.

  • Quarterly Short-term Investments fell 34.29% to $127.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $127.0 million through Dec 2025, down 34.29% year-over-year, with the annual reading at $127.0 million for FY2025, 34.29% down from the prior year.
  • Short-term Investments was $127.0 million for Q4 2025 at Caribou Biosciences, down from $136.1 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $277.7 million in Q4 2023 and troughed at $127.0 million in Q4 2025.
  • The 5-year median for Short-term Investments is $193.2 million (2024), against an average of $194.7 million.
  • Year-over-year, Short-term Investments soared 46.66% in 2023 and then plummeted 34.29% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $135.4 million in 2021, then surged by 39.81% to $189.3 million in 2022, then surged by 46.66% to $277.7 million in 2023, then crashed by 30.4% to $193.2 million in 2024, then plummeted by 34.29% to $127.0 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Short-term Investments are $127.0 million (Q4 2025), $136.1 million (Q3 2025), and $158.7 million (Q2 2025).